Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock [Yahoo! Finance]
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: Yahoo! Finance
Jan. 22, 2026, for a total transaction value of approximately ~$227,612, according to a SEC Form 4 filing Metric Value Shares sold (direct) Transaction value Post-transaction shares (direct) Post-transaction value (direct ownership) Transaction value based on SEC Form 4 weighted average purchase price ($45.52); post-transaction value based on Jan. 22, 2026 market close price (value derived from $45.52). What does the transaction reveal about Bachrodt's current ownership position? Following the immediate sale of 5,000 exercised shares, Bachrodt's direct common stock holdings decreased to 12,965 shares, equating to 0.0269% of Maze Therapeutics' outstanding shares as of Jan. 22, 2026. Did the transaction involve a Rule 10b5-1 trading plan? Yes, the sales were part of a Rule 10b5-1 trading plan, which allows an insider to schedule the addition or sale of shares in advance. Metric Value Employees Net income (TTM) -$101.46 million *1-year price change *1-
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MAZE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MAZE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $37.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
- Maze Therapeutics: An Innovative, Nature-Driven Platform [Seeking Alpha]Seeking Alpha
MAZE
Earnings
- 11/6/25 - Beat
MAZE
Sec Filings
- 2/2/26 - Form 4
- 1/26/26 - Form 4
- 1/16/26 - Form 144
- MAZE's page on the SEC website